BHVN ▼ -0.1% - Biohaven Ltd. $BHVN - Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease 08-OCT-2026 04:00 AM ET